Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.81 |
| ▸ | MMP2 | P08253 | 4/20 | 0.66 |
| ▸ | MMP3 | P08254 | 3/20 | 0.66 |
| ▸ | MMP13 | P45452 | 3/20 | 0.66 |
| ▸ | MMP9 | P14780 | 3/20 | 0.66 |
| ▸ | MMP1 | P03956 | 2/20 | 0.66 |
| ▸ | MMP7 | P09237 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.57 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.57 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL790069 | 1.00 | ADAMTS4 (0.81) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL702794 | 1.00 | ADAMTS4 (0.81) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| Trifluoroacetic Acid SCHEMBL7346536 | 0.90 | ADAMTS4 (0.68) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL1751961 | 0.90 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL4651862 | 0.90 | ADAMTS4 (1.00) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL17318887 | 0.86 | ADAMTS4 (0.62) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL14217417 | 0.85 | MMP9 (0.74) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL6798909 | 0.85 | ADAMTS4 (0.70) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL791357 | 0.85 | ADAMTS4 (0.61) | ADAMTS4MMP2MMP3MMP13MMP9 | |
| SCHEMBL3687103 | 0.85 | ADAMTS4 (0.61) | ADAMTS4MMP2MMP3MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | claimed |
| EP-3653607-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPBAU E K (DE) | 2023-10-18 | — | — | EP | claimed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | claimed |
| EP-3653607-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatenbau e.K. (DE) | 2020-05-20 | — | — | EP | claimed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | claimed |
| EP-2958894-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2015-12-30 | — | — | EP | claimed |
| WO-2014128139-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-08-28 | — | — | WO | claimed |
| CN-101180029-B | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD | 2011-02-16 | — | — | CN | claimed |
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| CN-101180029-A | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD (JP) | 2008-05-14 | — | — | CN | claimed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | claimed |
| EP-1307226-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | claimed |
| CN-1314895-A | Substituted piperazinones and therapeutic uses thereof | LAFON LABOR (FR) | 2001-09-26 | — | — | CN | claimed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | claimed |
| US-5929120-A | Guainidino, formamidino, amino and related compounds for inhibiting osteoclast-mediated bone resorption | MERCK & CO., INC. (US) | 1999-07-27 | — | — | US | claimed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | claimed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2024-02-13 | — | — | US | disclosed |
| WO-2024024915-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR PERIOSTIN-MEDIATED DISEASE AND PRURITUS ASSOCIATED THEREWITH | 国立大学法人佐賀大学 | 2024-02-01 | — | — | WO | disclosed |
| EP-4289819-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau e.K. (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-3653607-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPBAU E K (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2023-01-12 | — | — | US | disclosed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | disclosed |
| EP-3653607-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatenbau e.K. (DE) | 2020-05-20 | — | — | EP | disclosed |
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2020-03-19 | — | — | US | disclosed |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2019-11-05 | — | — | US | disclosed |
| US-9603819-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3048100-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2016-07-27 | — | — | EP | disclosed |
| EP-2435402-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2016-04-13 | — | — | EP | disclosed |
| EP-2958894-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2015-12-30 | — | — | EP | disclosed |
| CN-105102430-A | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPBAU KG | 2015-11-25 | — | — | CN | disclosed |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9006249-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2015-04-14 | — | — | US | disclosed |
| US-8937090-B2 | Parakeratosis inhibitor, pore-shrinking agent and external composition for skin | SHISEIDO COMPANY, LTD. (JP) | 2015-01-20 | — | — | US | disclosed |
| WO-2014128139-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-08-28 | — | — | WO | disclosed |
| EP-2423211-B1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | KANEKA CORP (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2012-10-04 | — | — | US | disclosed |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | SHISEIDO COMPANY, LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8263629-B2 | Substituted aminobutyric derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| EP-2435402-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | Novartis AG (CH) | 2012-04-04 | — | — | EP | disclosed |
| EP-2423211-A1 | PROCESSES FOR PRODUCING (1S,6S)- OR (1R,6R)-CIS-2,8-DIAZABICYCLO[4.3.0]NONANE AND INTERMEDIATE THEREOF | Kaneka Corporation (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20110065794-A1 | Wrinkle-preventing and improving composition | SHISEIDO COMPANY, LTD. (JP) | 2011-03-17 | — | — | US | disclosed |
| CN-101180029-B | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD | 2011-02-16 | — | — | CN | disclosed |
| US-7888351-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-02-15 | — | — | US | disclosed |
| US-20110034462-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2011-02-10 | — | — | US | disclosed |
| WO-2010136474-A2 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100168468-A1 | WRINKLE-PREVENTING AND IMPROVING COMPOSITION | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20090281069-A1 | ORGANIC COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-11-12 | — | — | US | disclosed |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | SHISEIDO COMPANY LTD (JP) | 2009-08-27 | — | — | US | disclosed |
| EP-2007723-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-12-31 | — | — | EP | disclosed |
| CN-101227885-A | Wrinkle preventing/improving agent | SHISEIDO CO LTD (JP) | 2008-07-23 | — | — | CN | disclosed |
| CN-101180029-A | Parakeratosis inhibitor, pore-shrinking agent or agent for preventing and improving rough skin, and composition for external use on skin | SHISEIDO CO LTD (JP) | 2008-05-14 | — | — | CN | disclosed |
| EP-1908454-A1 | WRINKLE-PREVENTIVE/AMELIORATING AGENT | SHISEIDO COMPANY, LTD. (JP) | 2008-04-09 | — | — | EP | disclosed |
| EP-1884230-A1 | PARAKERATOSIS INHIBITOR, PORE-SHRINKING AGENT OR AGENT FOR PREVENTING/AMELIORATING ROUGH SKIN AND EXTERNAL COMPOSITION FOR SKIN | Shiseido Company, Limited (JP) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007115821-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| CN-1173957-C | Substituted piperazones and their therapeutic use | L���������鹫˾ | 2004-11-03 | — | — | CN | disclosed |
| EP-1420831-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | Targesome, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003066624-A1 | PYRIMIDINONESULFAMOYLUREAS AS INTEGRIN LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2003-08-14 | — | — | WO | disclosed |
| EP-1307226-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2003011345-A1 | LIPID CONSTRUCTS AS THERAPEUTIC AND IMAGING AGENTS | TARGESOME, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| CN-1355811-A | Integrain receptor antagaonists | BASF AG (DE) | 2002-06-26 | — | — | CN | disclosed |
| WO-2001097848-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
| CN-1076345-C | 2,3-diaminopropionic acid derivative | SUMITOMO PHARMA (JP) | 2001-12-19 | — | — | CN | disclosed |
| EP-1140204-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| CN-1314895-A | Substituted piperazinones and therapeutic uses thereof | LAFON LABOR (FR) | 2001-09-26 | — | — | CN | disclosed |
| EP-1124824-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
| EP-1054871-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000035492-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-06-22 | — | — | WO | disclosed |
| WO-2000026212-A1 | CHROMENONE AND CHROMANONE DERIVATIVES AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2000-05-11 | — | — | WO | disclosed |
| WO-1999050249-A2 | PYRIMIDINES AND TRIAZINES AS INTEGRIN ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-10-07 | — | — | WO | disclosed |
| EP-0946166-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0944619-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | Du Pont Pharmaceuticals Company (US) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998043962-A1 | HETEROCYCLIC INTEGRIN INHIBITOR PRODRUGS | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-10-08 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998023608-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | DUPONT PHARMACEUTICALS COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |
| US-4618710-A | Preparation of optically active ketones | THE REGENTS OF THE UNIVERSITY OF CALIF. (US) | 1986-10-21 | — | — | US | disclosed |
| US-4618710-A | Preparation of optically active ketones | THE REGENTS OF THE UNIVERSITY OF CALIF. (US) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885 |
| US-20120252830-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ADAMTS4 732/4885MMP2 1240/4885MMP3 520/4885 |
| US-20150174089-A1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, GABRB1, GABRE | ADAMTS4 732/4885MMP2 1240/4885MMP3 520/4885 |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885 |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4764/4885MMP2 4338/4885MMP3 3434/4885 |
| US-20100305145-A1 | Substituted Aminobutyric Derivatives as Neprilysin Inhibitors | MME, GABRB1, GABRE | ADAMTS4 732/4885MMP2 1240/4885MMP3 520/4885 |
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4756/4885MMP2 4358/4885MMP3 3323/4885 |
| US-20120232111-A1 | Parakeratosis inhibitor, pore -shrinking agent and external compositon for skin | CUTA, AAAS, NUP160 | ADAMTS4 1706/4885MMP2 1316/4885MMP3 908/4885 |
| US-20090215893-A1 | Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin | CUTA, STOM, MTOR | ADAMTS4 3345/4885MMP2 1673/4885MMP3 1827/4885 |
| US-20090281069-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ADAMTS4 1828/4885MMP2 2243/4885MMP3 1623/4885 |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4743/4885MMP2 4285/4885MMP3 3338/4885 |
| US-20100168468-A1 | WRINKLE-PREVENTING AND IMPROVING COMPOSITION | COL1A1, COL2A1, COL14A1 | ADAMTS4 3075/4885MMP2 626/4885MMP3 517/4885 |
| US-20110034462-A1 | ORGANIC COMPOUNDS | OTC, OAT, SLCO2B1 | ADAMTS4 1828/4885MMP2 2243/4885MMP3 1623/4885 |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | ADAMTS4 4743/4885MMP2 4285/4885MMP3 3338/4885 |
| US-20110065794-A1 | Wrinkle-preventing and improving composition | COL1A1, COL2A1, COL14A1 | ADAMTS4 3075/4885MMP2 626/4885MMP3 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.